search
Back to results

Monitor-Guided Analgesia During General Anesthesia - Part II (MOGADA-II)

Primary Purpose

Pain, Postoperative, Pain, Nociceptive Pain

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Opioid administration (remifentanil) in intervention group
Opioid administration (remifentanil) in control group
Sponsored by
Universitätsklinikum Hamburg-Eppendorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Analgesia, Monitoring, Opioid, Sufentanil, Sevoflurane

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Radical open abdominal prostatectomy scheduled in the operation theater where the study is conducted
  • > 18 years

Exclusion Criteria:

  • Chronic opioid therapy
  • Beta blocker and digitalis therapy
  • Eye disease with affection of pupil reactivity
  • Pacemaker therapy
  • Higher degrees of cardiac arrhythmias, e.g. atrial fibrillation
  • Pre-operative medication with steroids

Sites / Locations

  • Department of Anesthesiology; Center of Anesthesiology and Intensive Care Medicine, Hamburg Eppendorf University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

PPI (Pain Pupillary Index)

SPI (Surgical Pleth Index)

NOL (Nociception Level)

Control

Arm Description

Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.

Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.

Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.

Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.

Outcomes

Primary Outcome Measures

Intraoperative opioid consumption
Compares the amount of intraoperative opioid administration (remifentanil) per minute of general anesthesia and per kg bodyweight between groups.

Secondary Outcome Measures

Time to extubation
Postoperative recovery time: Time interval between end of operation and tracheal extubation of the patient.
Time to Fit-for-discharge
Postoperative recovery time: Time interval between postoperative tracheal extubation and the patient reaching fit-for-discharge criteria. criteria from the PACU to the ward.
Postoperative pain level
Postoperative pain level measured with the highest score in numeric pain rating scale (NRS).
Postoperative opioid administration
Amount of postoperative opioid administration (piritramid) in the postanesthesia care unit (PACU). Piritramid is given if NRS score is > 3.
Patient satisfaction
Patient satisfaction with the general anesthesia and pain management evaluated by a numeric rating scale.
Release of stress hormones
Amount of perioperative plasma level of cortisol and ACTH.

Full Information

First Posted
November 29, 2017
Last Updated
April 28, 2019
Sponsor
Universitätsklinikum Hamburg-Eppendorf
search

1. Study Identification

Unique Protocol Identification Number
NCT03380949
Brief Title
Monitor-Guided Analgesia During General Anesthesia - Part II
Acronym
MOGADA-II
Official Title
Investigation of the Effect of Opioid Titration Guided by Analgesia Indices During Total Intravenous Anesthesia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
December 8, 2017 (Actual)
Primary Completion Date
April 18, 2018 (Actual)
Study Completion Date
June 7, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitätsklinikum Hamburg-Eppendorf

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This prospective randomized clinical trial evaluates the effects of a monitor-guided opioid analgesia during general anesthesia. To date no standard-monitoring device exists to specifically reflect the analgesic component of general anesthesia. Quality and safety of general anesthesia are of major clinical importance and should be improved by limiting the opioid analgesic's dosage to the minimum amount needed. The study compares the effects of monitoring nociception during general anesthesia with different innovative techniques in comparison to routine clinical practice.
Detailed Description
This prospective randomized clinical study aims to investigate the effects of a monitor-guided opioid analgesia during general anesthesia by different monitoring systems in comparison to routine clinical practice. Many surgical procedures require general anesthesia. The main components of general anesthesia are hypnosis and analgesia, and anesthesiologists usually combine a hypnotic drug with an opioid analgesic. Until today, however, there is no standard-monitoring of nociception to specifically reflect the analgesic component of general anesthesia. In clinical practice the opioid dosage is chosen by clinical judgment of the attending anesthesiologist based upon changes of heart rate, blood pressure, pupil size, lacrimation and sweating of the patient. On the one hand, underdosage of opioids can cause nociception leading to an increased sympathetic tone, increase of plasma levels of stress hormones, nociceptive movements as well as increase postoperative pain. On the other hand, overdosage of opioids can lead to drug side effects such as nausea and vomiting, hemodynamic instability, an increase in recovery times, immunosuppression and an increase in postoperative pain by opioid-induced-hyperalgesia. Quality and safety of general anesthesia are of major clinical importance and can be improved by limiting the administration of opioid analgesics to the optimal individual dose needed. In the last years, different analgesia monitoring devices have been developed for monitoring nociception. The present study evaluates the effects of the administration of opioids during general anesthesia guided by three different monitoring systems in comparison to routine clinical practice. All patients will receive general anesthesia with propofol guided by bispectral index (BIS) with a target of BIS values between 40 and 60. Opioid administration will be guided by one of three analgesic monitoring devices or the interpretation of clinical signs by the attending anesthesiologist in the control group. After institutional approval by the Ethics committee of the Medical Board of the City of Hamburg, Germany and obtaining patients' written informed consent we randomize elective patients with major abdominal surgery for open radical prostatectomy into one of four treatment groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Pain, Nociceptive Pain, Opioid Use, Analgesia
Keywords
Analgesia, Monitoring, Opioid, Sufentanil, Sevoflurane

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are assigned to intervention groups by chance
Masking
ParticipantOutcomes Assessor
Masking Description
Participants are not informed about the group assignement (intervention takes place in general anesthesia). Outcome assessors are persons without knowledge on former treatment in intervention/control group.
Allocation
Randomized
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PPI (Pain Pupillary Index)
Arm Type
Experimental
Arm Description
Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
Arm Title
SPI (Surgical Pleth Index)
Arm Type
Experimental
Arm Description
Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
Arm Title
NOL (Nociception Level)
Arm Type
Experimental
Arm Description
Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
Intervention Type
Procedure
Intervention Name(s)
Opioid administration (remifentanil) in intervention group
Intervention Description
Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
Intervention Type
Procedure
Intervention Name(s)
Opioid administration (remifentanil) in control group
Intervention Description
Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
Primary Outcome Measure Information:
Title
Intraoperative opioid consumption
Description
Compares the amount of intraoperative opioid administration (remifentanil) per minute of general anesthesia and per kg bodyweight between groups.
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Time to extubation
Description
Postoperative recovery time: Time interval between end of operation and tracheal extubation of the patient.
Time Frame
1 day
Title
Time to Fit-for-discharge
Description
Postoperative recovery time: Time interval between postoperative tracheal extubation and the patient reaching fit-for-discharge criteria. criteria from the PACU to the ward.
Time Frame
1 day
Title
Postoperative pain level
Description
Postoperative pain level measured with the highest score in numeric pain rating scale (NRS).
Time Frame
1 day
Title
Postoperative opioid administration
Description
Amount of postoperative opioid administration (piritramid) in the postanesthesia care unit (PACU). Piritramid is given if NRS score is > 3.
Time Frame
1 day
Title
Patient satisfaction
Description
Patient satisfaction with the general anesthesia and pain management evaluated by a numeric rating scale.
Time Frame
2-21 days
Title
Release of stress hormones
Description
Amount of perioperative plasma level of cortisol and ACTH.
Time Frame
1 day

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Radical open abdominal prostatectomy scheduled in the operation theater where the study is conducted > 18 years Exclusion Criteria: Chronic opioid therapy Beta blocker and digitalis therapy Eye disease with affection of pupil reactivity Pacemaker therapy Higher degrees of cardiac arrhythmias, e.g. atrial fibrillation Pre-operative medication with steroids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rainer Nitzschke, MD
Organizational Affiliation
Department of Anesthesiology, Hamburg Eppendorf University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sandra Funcke, MD
Organizational Affiliation
Department of Anesthesiology, Hamburg Eppendorf University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Anesthesiology; Center of Anesthesiology and Intensive Care Medicine, Hamburg Eppendorf University Medical Center
City
Hamburg
ZIP/Postal Code
20246
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
All data will be anonymized before publication.
Citations:
PubMed Identifier
33228979
Citation
Funcke S, Pinnschmidt HO, Brinkmann C, Wesseler S, Beyer B, Fischer M, Nitzschke R. Nociception level-guided opioid administration in radical retropubic prostatectomy: a randomised controlled trial. Br J Anaesth. 2021 Feb;126(2):516-524. doi: 10.1016/j.bja.2020.09.051. Epub 2020 Nov 20.
Results Reference
derived

Learn more about this trial

Monitor-Guided Analgesia During General Anesthesia - Part II

We'll reach out to this number within 24 hrs